Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›BNTX›BNT162b2

BNT162b2

Ensayo de BioNTech SE en Infección por SARS-CoV-2 · COVID-19.

Más ensayos de: COVID-19.

Todo sobre el fármaco: BNT162b2.

Fase
Fase 2/3
Estado
Completado
Participantes
1.051
previstos
Centros
37
Fin del objetivo primario
mar 2025
fecha real

Título oficial en el registro (en inglés): A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en ago 2023.

De principio a fin

  1. Empieza el ensayo (ago 2023)
  2. Lectura de resultados mar 2025 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Porcentaje de participantes con reacciones locales dentro de los 7 dias posteriores a la vacunacion: SSA (Day 1 to Day 7 after vaccination) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people. Substudy A: * This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, * in people who are 12 years of age and older, * who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1). * The study is about 6 months long for each participant. * Participants will have at least 5 visits to the clinic. * At each clinic visit a blood sample will be taken. * At least 1 nasal swab will taken. Substudy B: * This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, * in people who are 12 years of age and older, * who are COVID-19 vaccine-naïve * who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration. * The study is about 6 months long for each participant. * Participants will have at least 5 visits to the clinic. * At each clinic visit a blood sample will be taken. * At least 1 nasal swab will taken. Substudy C: * This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to: * Cohort 1: people who are 18 years of age and older, who will receive BNT162b2 (Omi JN.1), and, * Cohort 2: people who are 12 years of age and older, who will receive BNT162b2 (Omi JN.1), and, * Cohort 3: people who are 18 years of age and older who will receive BNT162b2 (Omi KP.2). * Participants may have never received a COVID-19 vaccine or, may have previously received COVID-19 vaccine(s), with the most recent dose received at least 150 days before the study vaccination (Visit 1). * The study is about 6 months long for each participant. * Participants will have at least 6 visits (Cohorts 1 and 3) or at least 5 visits (Cohort 2) to the clinic. * At each clinic visit a blood sample will be taken. * At least 1 nasal swab will taken.

Sigue a BNTX y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de BNTX

EnsayoFaseEstadoLectura de resultados
BNT164a1Fase 1/2En marcha, sin reclutarmar 2026 (real)
BNT314Fase 1En marcha, sin reclutarago 2026 (real)
BNT163Fase 1En marcha, sin reclutaroct 2026 (prevista, ya pasada: sin actualizar en el registro)
RO7198457 intravenousFase 2En marcha, sin reclutarnov 2026 (prevista)
BNT351Fase 1Reclutando pacientesnov 2026 (prevista)
BNT162b2Fase 3En marcha, sin reclutarabr 2027 (prevista)

Todos los de BNTX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05997290), actualizada en abr 2026.